Therefore, it would be important to investigate in future studies whether inhibiting p53 activation can desensitize MCC cells to PRMT5 deficiency or whether overexpressing MYC is synergistically lethal with PRMT5 inhibition. This evidence concerns the gene MYC and Merkel cell skin cancer.